Author: Nichols Martin|| Date Published: September 28, 2018
The Food and Drug Administration has awarded four companies contracts worth up to $75M each to develop automated methods for reporting adverse drug events.
IBM (NYSE: IBM), Acumen, Dovel Technologiesand IQVIA Government Solutions will use artificial intelligence, machine learning, natural language processing and other automation techniques to create data collection and analysis systems for the FDA’s Center for Biologics Evaluation and Research, the agency said Thursday in a FedBizOpps notice.
FDA requires each contractor to offer indirect access to medical information of U.S. patients, including administrative and claims data and electronic health records.
The indefinite delivery/indefinite quantity contracts have a five-year ordering period.
The agency also selected the four companies to develop surveillance tools as part of the Biologics Effectiveness and Safety Initiative.
CACI International has secured a potential five-year, $416 million SeaPort-Next Generation task order to sustain and modernize information technology systems…
Cherry Bekaert has acquired accounting and advisory firm Tarsus to expand outsourced accounting, real-time financial reporting and strategic chief financial…
General Dynamics Information Technology has received a U.S. Navy contract worth $988 million to modernize and integrate command, control, communications,…
Dave Wajsgras, an eight-time Wash100 Award winner, has been named chairman and CEO of Everfox. The cybersecurity company said Monday that Wajsgras will…
The Transportation Security Administration has announced a contract opportunity with an estimated value exceeding $100 million for enterprise-wide IT support…
The Food and Drug Administration has awarded four companies contracts worth up to $75M each to develop automated methods for reporting adverse drug events.
